Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

November 3rd 2014

In the Literature: microRNA Biomarkers For Early Detection of Childhood Cancers

Research to be presented this week at the National Cancer Research Institute Cancer Conference has identified the expression of specific serum microRNAs in pediatric solid tumors, which could prove useful for early diagnosis.

November 3rd 2014

Physician Fee Schedule and Hospital Outpatient Payment System: Updates by CMS

CMS released final rules for both the 2015 Medicare Physician Fee Schedule and the 2015 Hospital Outpatient Prospective Payment System.

November 2nd 2014

Test Predicts Benefit of Extended Endocrine Therapy in Breast Cancer Patients

bioTheranostics, Inc's Breast Cancer Index, a genomic test quantifying the risk of breast cancer recurrence and predicting which patients will likely benefit from extended endocrine therapy, will be covered by Medicare.

November 2nd 2014

After Drones and a Smart Eye Device, Google Introduces An Early Disease Tracer

Google is aiming to diagnose cancers, impending heart attacks or strokes and other diseases, at a much earlier stage than is currently possible.

November 1st 2014

CTFPHC: Do Not Use PSA to Screen for Prostate Cancer

The guideline, published in the Canadian Medical Association Journal, recommends against using PSA to screen for prostate cancer, pointing to the high risk of false positives and overdiagnosis.

October 31st 2014

Computer-Aided Mammograms Increase Medicare Cost-Burden: JAMA Study

The retrospective study analyzed SEER data from 2001 through 2009, and found that the annual CAD prevalence among Medicare screening mammograms increased from 3.5% to 79.7%.

October 31st 2014

Diagnostic Lung Biopsies a Big Drain on Medicare, Study Finds

The retrospective study, results of which were presented at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, showed that the total diagnostic workup cost for the study sample of Medicare beneficiaries was $38.3 million.

October 30th 2014

Mental Health Issues Overshadow Breast Cancer Survivorship

The Danish study, published in the Journal of Clinical Oncology, identified a 70% greater risk of severe depression in the first year after diagnosis.

October 30th 2014

After Pembrolizumab, Promising Results With Nivolumab in NSCLC

Phase 2 results from the Checkmate-063 trial found that treatment with the PD-1 inhibitor Nivolumab (Opdivo) resulted in a median OS of 8.2 months in NSCLC patients who had received 2 prior treatments.

October 30th 2014

EMA Grants Orphan Status to Kiadis Pharma's Immuno-oncology Molecule

The European Medicines Agency granted an orphan status to ATIR, a T-cell immunotherapy-based medicinal product being developed to treat blood cancers.

October 29th 2014

Prostate Cancer Screening Remains Highly Debated

While the USPSTF recommended against screening for prostate cancer, citing the high rate of false positives, complications from biopsy, and side-effects of aggressive treatment for a sometimes slowly-progressing disease, several medical organizations disagree.

October 28th 2014

Nanodevice to Help Titrate and Individualize Chemotherapy

A miniature device can measure a patient's blood for methotrexate, a commonly used but potentially toxic cancer drug.

October 28th 2014

From Diagnostics to Cancer Drug Costs, Nothing's Off Limits at AJMCLive's Patient-Centered Oncology Care

The toughest topics in cancer care will be on tap November 13-14, 2014, in Baltimore, Maryland, when AJMCLive presents Patient-Centered Oncology Care. If you've followed the discussion among pharmaceutical leaders, oncologists, and payers over access to care, you'll want to join stakeholders to discuss how to ensure patients get what they need while controlling costs.

October 28th 2014

Friction Between Health Plans, Pharma Grows Over Specialty Drugs

Mary K. Caffrey

The war of words between managed care and pharmaceutical manufacturers, which began when Gilead set the price for its drug to treat the hepatitis C virus (HCV), has taken off in October with the reclassification of a trio of cancer drugs from Genentech. Growth in the "specialty pharma" sector, where prices are rising much faster than drug prices generally, has drawn concern from payers and the umbrella group that represents them, while the trade group that represents drugmakers is pushing back against critics, saying that it faces challenges in bringing life-saving therapies to market.

October 27th 2014

Breakthrough Designation for Merck's Keytruda in NSCLC

Recently approved as second-line treatment of metastatic melanoma, following resistance to ipilimumab, the FDA has now designated Keytruda as breakthrough therapy to treat EGFR-mutation and ALK-rearrangement negative NSCLC patients who have pr0gressed following platinum-based therapy.

October 27th 2014

Breast Cancer Risk Increased Following Chest Irradiation in Children

Radiation exposure due to chest irradiation in women who had childhood Wilms tumor increased their susceptibility to developing breast cancer later in life.

October 27th 2014

Merck's Rapid Strides With Pembrolizumab

Surabhi Dangi-Garimella, PhD

Today, Merck announced that Keytruda has been granted breakthrough therapy designation for treating patients with epidermal growth factor receptor mutation-negative and anaplastic lymphoma kinase rearrangement-negative non-small cell lung cancer (NSCLC).

October 27th 2014

Scientists Identify a Novel Wnt Signaling Regulator in Colorectal and Endometrial Cancers

The gene mutation in RNF43, previously missed in The Cancer Genome Atlas study, was identified in 20% of colorectal and endometrial cancers.

October 26th 2014

Evidence Shows Improved OS With Delayed Radiation Following Glioblastoma Surgery

The UCSF study identified a window of 30 to 35 days post surgery, following surgery in patients with glioblastoma multiforme, when delayed radiation significantly improved OS and PFS.

October 26th 2014

Nanotechnology Can Aid Early Cancer Diagnosis

This novel fluorescent imaging technique uses shortwave IR, which has much better tissue penetration than near-IR currently used in imaging.

October 26th 2014

In the Literature: A Speech Gene Prevents Breast Cancer Metastasis

The study, published in Cell Stem Cell, identified a microRNA-mediated inhibitory pathway that repressed expression of the speech and language gene FOXP2, promoting metastases of breast cancer cells to distant sites.

October 25th 2014

Quality of Care Takes Precedence for Breast Cancer Patients in New Jersey

Horizon BCBS partners with RCCA to improve quality of care for breast cancer patients by evaluating their molecular subtype before administering treatment.

October 25th 2014

MIT Scientists Develop A Rapid Modeling Technique for Cancer Gene Mutations

The group, led by Koch Institute director Tyler Jacks, used CRISPR to generate mutant genes that were then packaged into enteroviruses that were used to infect target organs in mice. This is a much faster process than the traditional method that need crossing genetically-engineered mice.

October 24th 2014

VeriStrat Proteomic Test Approved by NCCN for Inclusion in NSCLC Treatment

October 23rd 2014

Collaborative Model Succeeds in Reducing Cancer Patient Readmissions

Oncologists and palliative care specialists at Duke University Hospital worked together in patient care, resulting in a 23% reduction in patient readmission within a week of discharge.

October 22nd 2014

Everolimus Under FDA Scrutiny For Potential Risk

Everolimus has been added to FDA's Adverse Event Reporting System due to a possible risk of hypertension.

October 21st 2014

Fast Track for Taiho Oncology's mCRC Molecule

Taiho Oncology, Inc, announced that the FDA granted Fast Track designation for an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer.

October 21st 2014

In the Literature: New Lead in Treating ALL

The paper, published in Nature, has identified a "switch" that can be inhibited to restrict tumor growth.

October 20th 2014

A SNP That Affords Protection From Breast Cancer Identified

The study, published in the journal Nature Communications, identified the single nucleotide polymorphism near the coding region of the estrogen receptor ESR1 among Latina women.

October 20th 2014

Including Panobinostat Improves PFS in Multiple Myeloma

Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.

...

150 151 152 153 154 155 156 157 158

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions